aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
10. Dezember 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13. August 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
14. Mai 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma to Present at Upcoming Investor Conferences
06. Mai 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences.
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
02. Mai 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
21. Februar 2024 08:00 ET
|
aTyr Pharma, Inc.
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10. November 2022 16:00 ET
|
aTyr Pharma, Inc.
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
09. November 2022 08:00 ET
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
27. September 2022 08:00 ET
|
aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
01. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...